//

Binaytara Foundation Fellow & Resident Abstract Award Winners for 2022 Summit on Cancer Health Disparities Announced

1 min read
world map

Seattle, WA, April 6, 2022 – The Binaytara Foundation, a non-profit organization that works to improve equity in cancer care, has announced three Fellow & Resident Abstract Award winners for the 2022 Summit on Cancer Health Disparities (April 29 – May 1). This year’s recipients are:

·        Dr. Gladys M. Rodriguez from Stanford University for her abstract, “Addressing Latinx CANcer Care Equity (ALCANCE) Randomized Controlled Trial: Baseline Findings from a Community Health Worker-Led Intervention.” 

·        Dr. Utsav Joshi, a resident at Rochester General Hospital, for his abstract, “Factors Affecting Utilization of Chemotherapy in Acute Lymphoblastic Leukemia (ALL): A SEER Database Study.”

·        Dr. Pravash Budhathoki, a resident at Bronx-Lebanon Hospital Center, for his abstract, “Disparities in Breast Cancer Genomic Signature Ordering Practices in the United States.”

     “We would like to congratulate all three winners on their accomplishments,” says Binaytara Foundation president Dr. Binay Shah. “Their research has contributed to our knowledge of disparities in cancer care, which helps with our mission to reduce inequity and improve access to cancer treatment.”

Abstracts will be presented at the 2022 Summit on Cancer Health Disparities, which will be held from April 29th to May 1st, 2022 at the Grand Hyatt in Seattle. Two abstract sessions will be held on May 1st. Please click here to register for the summit.

The 2022 Summit on Cancer Health Disparities will bring together oncology professionals, cancer disparity researchers, and other stakeholders to discuss the factors leading to cancer health inequities. Additionally, they will explore ways to overcome the impact of these factors to optimize outcomes of cancer patients.

About Binaytara Foundation:

Binaytara Foundation is a global cancer non-profit dedicated to improving access to cancer care in the United States and abroad through education and innovative program models that break down barriers and advance best practices in hematology and oncology. Binaytara Foundation’s major projects include hematology and oncology conferences, and the establishment of a cancer hospital in Nepal.

Latest from Blog

HER2CLIMB-02

By Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center   Tucatinib, a HER2-directed tyrosine kinase

INAVO120 trial

By Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center   Development of endocrine resistance remains